Radiation therapy systems firm Accuray Q1 revenue down 7%, net loss widens

Accuray

05/11/2025 21:42

Overview

Accuray fiscal Q1 2026 rev down 7% yr/yr, but beats analysts' expectations

Net loss widens significantly from prior year

Company initiated restructuring plan, incurring $2.8 mln in charges

Outlook

Accuray reaffirms fiscal 2026 revenue guidance of $471 mln to $485 mln

Accuray expects fiscal 2026 adjusted EBITDA of $31 mln to $35 mln

Company focuses on strategic transformation and restructuring for future growth

Result Drivers

RESTRUCTURING PLAN - Co initiated restructuring to reduce costs and streamline operations, incurring $2.8 mln in charges

SERVICE REVENUE INCREASE - Service revenue grew 7% yr/yr, offsetting decline in product revenue

PRODUCT INTRODUCTION - Introduction of Accuray Stellar Solution in U.S. market seen as growth opportunity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$93.94 mln
$92.20 mln (3 Analysts)
Q1 Net Income
-$21.68 mln
Q1 Basic EPS
-$0.18
Q1 Gross Profit
$26.55 mln
Q1 Income From Operations
-$11.31 mln
Q1 Operating Expenses
$37.86 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Accuray Inc is $4.75, about 70.9% above its November 4 closing price of $1.38

Press Release: ID:nPn2SsZNga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)